Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Trading Down 0.4% – Here’s Why

Shares of Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) dropped 0.4% during mid-day trading on Friday . The company traded as low as $5.28 and last traded at $5.50. Approximately 104,772 shares traded hands during trading, a decline of 86% from the average daily volume of 760,983 shares. The stock had previously closed at $5.52.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price target on Neuphoria Therapeutics Inc. – Common Stock from $8.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, February 4th.

Neuphoria Therapeutics Inc. – Common Stock Price Performance

The company has a 50-day simple moving average of $4.58.

Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) last issued its quarterly earnings results on Friday, February 14th. The company reported ($1.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.01) by $0.78. The business had revenue of $660 billion for the quarter. Research analysts predict that Neuphoria Therapeutics Inc. – Common Stock will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Neuphoria Therapeutics Inc. – Common Stock

An institutional investor recently bought a new position in Neuphoria Therapeutics Inc. – Common Stock stock. Lynx1 Capital Management LP bought a new stake in Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 45,806 shares of the company’s stock, valued at approximately $157,000. Neuphoria Therapeutics Inc. – Common Stock accounts for about 0.1% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th largest position. Lynx1 Capital Management LP owned 2.81% of Neuphoria Therapeutics Inc. – Common Stock as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Inc. – Common Stock Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.